Top Page
Inspira Technologies Oxy BHN
(NASDAQ:IINN)
Inspira Technologies Oxy BHN (IINN) vs. SPDR S&P 500 ETF (SPY)
Inspira Technologies Oxy BHN Business Overview & Revenue Model
Inspira Technologies Oxy BHN Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 289.00K | 0.00 | 0.00 | -4.68M | 0.00 | 0.00 |
| Gross Profit | 2.00K | -488.00K | -406.00K | -5.04M | -218.00K | -203.00K |
| EBITDA | -7.16M | -11.10K | -10.87M | -14.68M | -16.72M | -6.96M |
| Net Income | -6.40M | -11.05K | -11.29M | -4.00M | -16.96M | -7.23M |
Balance Sheet | ||||||
| Total Assets | 4.45M | 8.07M | 9.31M | 16.01M | 25.87M | 987.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 5.78M | 7.36M | 13.90M | 23.75M | 496.00K |
| Total Debt | 640.00K | 2.51M | 878.00K | 1.46M | 1.48M | 2.32M |
| Total Liabilities | 3.17M | 3.75M | 3.57M | 3.19M | 5.52M | 2.69M |
| Stockholders Equity | 1.28M | 4.32M | 5.74M | 13.63M | 20.35M | -1.70M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -9.54M | -9.96M | -7.68M | -8.05M | -1.90M |
| Operating Cash Flow | 0.00 | -9.37M | -9.76M | -7.38M | -7.88M | -1.88M |
| Investing Cash Flow | 0.00 | 1.49M | 4.59M | -7.25M | -246.00K | -26.00K |
| Financing Cash Flow | 0.00 | 7.90M | 3.45M | -399.00K | 30.42M | 2.29M |
Inspira Technologies Oxy BHN Technical Analysis
Inspira Technologies Oxy BHN Risk Analysis
Inspira Technologies Oxy BHN Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $3.55B | -16.19 | -17.63% | ― | 8.97% | -1024.86% | |
54 Neutral | $191.92M | -3.41 | -34.75% | ― | 15.19% | -3.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $86.62M | -1.49 | -73.73% | ― | 15.59% | 4.13% | |
44 Neutral | $42.27M | -3.54 | -96.15% | ― | -8.97% | 47.29% | |
44 Neutral | $7.64M | -0.13 | -179.63% | ― | 147.74% | 73.23% | |
42 Neutral | $33.57M | -2.04 | ― | ― | ― | ― |
Inspira Technologies Oxy BHN Corporate Events
On January 5, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed a non-binding term sheet to acquire an advanced liquid biopsy cancer diagnostics business in an all-share deal, exchanging 40% of its fully diluted share capital and securing a concurrent $15 million strategic equity investment at a pre-money valuation of $180 million. The move would shift Inspira into the fast-growing liquid biopsy market via a development-ready platform that uses AI to analyze circulating tumor cells, initially focused on breast cancer, with plans to pursue FDA 510(k) clearance and benefit from an existing reimbursement code. To bridge the period until a definitive acquisition agreement, Inspira also issued a binding senior convertible debenture on January 5, 2026, lending the target company $1 million at 10% annual interest, with conversion features tied to Tel Aviv Stock Exchange rules and a 19.99% ownership cap. The company intends to allocate up to $12 million of the new equity proceeds to support its existing respiratory and blood monitoring operations, while a contingent value rights structure is designed to preserve the economic upside from these legacy assets exclusively for current shareholders, underscoring management’s effort to mitigate dilution and reposition Inspira as a dual-platform MedTech player spanning life-support and oncology diagnostics.
The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Inspira Technologies Oxy B.H.N. Ltd., an Israeli foreign private issuer listed in the United States, operates within the medical technology and healthcare sector, though this filing focuses on its corporate governance and regulatory compliance rather than its products or services.
On December 30, 2025, the company convened its Annual and Extraordinary General Meeting of Shareholders, which was initially adjourned at 4:00 p.m. Israel time due to lack of quorum but successfully reconvened and held at 6:00 p.m., when a quorum was present and shareholders approved the agenda item described in the previously distributed notice and proxy statement; the resulting Form 6-K has been incorporated by reference into several of Inspira Technologies’ existing U.S. securities registration statements, underscoring its ongoing compliance with SEC reporting and governance requirements.
The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. reaffirmed that previously announced binding purchase orders totaling $49.5 million remain valid and in full force, based on confirmations from its distribution partner. The company said the payment and execution framework for these orders has been rescheduled to begin with the 2026 fiscal year, aligning cash collection and revenue recognition with regulatory sequencing, technical implementation needs, and institutional funding timelines for large-scale international healthcare deployments. By coordinating closely with regulators, distribution partners, and funding organizations, Inspira aims to reduce execution risk, improve operational visibility, and support a phased rollout of its technologies across target markets, with further updates expected as 2026 regulatory and deployment milestones are reached.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 12, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a registered direct offering agreement with YA II PN, Ltd., involving the issuance of 1,565,217 ordinary shares at $1.15 per share, expected to generate $1.8 million in gross proceeds. Additionally, the company entered into a Standby Equity Purchase Agreement (SEPA) with YA, allowing for up to $25 million in equity financing over 36 months. These financial maneuvers aim to bolster Inspira’s working capital and support its strategic roadmap, enhancing its operational flexibility and market positioning.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 9, 2025, Inspira Technologies announced that it has been granted a patent in Japan for its Convertible Dual Lumen Cannula device, securing exclusive rights in a major medical device market until 2041. This patent complements their existing U.S. patent, enhancing their position in two of the largest healthcare economies. The innovative design of the cannula allows conversion from single to dual-lumen intravascularly, potentially reducing infection risks and procedural costs. This development solidifies Inspira’s foundation for respiratory support platforms and future disposable revenue streams.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On December 3, 2025, Inspira Technologies announced a strategic expansion of its blood laboratory capabilities, marking a significant step in its evolution towards cutting-edge diagnostic technologies. This expansion involves moving to a larger facility, increasing recruitment of specialized personnel, and upgrading research instrumentation. The new laboratory is expected to enhance sample processing capacity and integrate advanced diagnostic technologies, positioning Inspira for accelerated growth and addressing high-value medical needs. This development is seen as a foundation for aggressive business growth, potentially generating long-term value for patients and shareholders.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Inspira Technologies Oxy B.H.N. Ltd. has announced its upcoming Annual and Extraordinary General Meeting of Shareholders, scheduled for December 30, 2025, in Ra’anana, Israel. The meeting will address several key proposals, including the re-appointment of Ziv Haft as the company’s independent auditor, the re-election of board members, and the approval of restricted share units for a new director. This meeting is significant for stakeholders as it involves decisions on leadership and financial oversight, impacting the company’s strategic direction and governance.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On November 13, 2025, Inspira Technologies announced the completion of a clinical study for its HYLA blood sensor, a non-invasive device designed for real-time blood monitoring. The study showed accuracy levels between 95% to 99%, and the company is now moving towards final validation and regulatory submission. This development enhances Inspira’s market positioning by potentially offering a disruptive solution in critical-care environments, supporting patient safety and workflow efficiency.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On November 6, 2025, Inspira Technologies announced the completion of its regulatory submission for the ART100 system to the UAE Ministry of Health and Prevention, with final approval expected soon. This milestone is part of Inspira’s strategy to expand in the Gulf region, leveraging the UAE’s efficient regulatory framework. The anticipated authorization is expected to enhance regional partnerships and unlock commercialization potential across the Middle East’s healthcare networks.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On October 22, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a strategic collaboration with Bites Learning Ltd. to integrate AI-based digital training solutions across Inspira’s ecosystem. This partnership aims to enhance training, onboarding, and operational performance for Inspira’s products, including the INSPIRA™ ART100 system and the HYLA™ blood sensor. The collaboration is expected to improve operational consistency, expand adoption, and strengthen Inspira’s global execution, ultimately driving shareholder value and setting a new industry standard.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
On October 21, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced significant leadership changes to enhance its global commercialization and governance. The company appointed Mike Hershkovitz as Vice President of Global Sales and Sivan Matza as an independent director on the board. Hershkovitz, with extensive experience in the healthcare market, will lead sales strategies, while Matza’s expertise in global finance will strengthen governance as the company expands. These appointments are expected to drive Inspira’s growth and operational execution, aligning with industry trends of consolidation and strategic partnerships.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.